Survival and side effects rates of radionuclide therapy of bone metastases by Sm-153 Oxabifore (Sm-153) with different complex and combined regimens: chemo-, target, bisphosphonates, and hormonal therapies

Bone is a common site of metastatic cancer which can either develop later or at the time of presentation. Bone metastasis can affect quality of life, adversely affect performance status, and affect survival. Both, patients with presentation of bone metastases at diagnosis of primary tumor and with relapse of disease need complex approach to therapy. Radionuclide therapy (RNT) has affinity to high bone turnover, by irradiation bone marrow (cancer cells) and specific populations of nerve fibers that innervate skeleton are used for reduction of pain syndrome. However, role of RNT in complex therapy of breast cancer (BC) on the stage of bone metastasis is unclear. According to our preliminary results on small groups of patients, all combinations with RNT were relatively safe. More frequently side effects were observed in Group III (Bis + chemo- + RNT). Promising results in survival rates were achieved in all groups of patients